Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

Vaccine

Volumn 28, Issue 3, 2010, Pages 632-649

  Guy, Bruno ^a   Guirakhoo, Farshad ^a   Barban, Veronique ^a   Higgs, Stephen ^b   Monath, Thomas P ^c   Lang, Jean ^a  

^a SANOFI PASTEUR   (France)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Kleiner Perkins Caufield & Byers   (United States)

Author keywords

Chimera; Dengue; Flavivirus; Japanese encephalitis; Vaccine; West Nile virus

Indexed keywords

DENGUE VACCINE; JAPANESE ENCEPHALITIS VACCINE; PLACEBO; WEST NILE VACCINE; YELLOW FEVER VACCINE;

BIOLOGICAL MODEL; CHIMERA; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; GENETIC STABILITY; HUMAN; JAPANESE ENCEPHALITIS VIRUS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

DENGUE VACCINES; DENGUE VIRUS; ENCEPHALITIS VIRUS, JAPANESE; GENETIC VECTORS; HUMANS; JAPANESE ENCEPHALITIS VACCINES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PROTEINS; WEST NILE VIRUS; WEST NILE VIRUS VACCINES; YELLOW FEVER VIRUS;

EID: 71449111221     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.098     Document Type: Review

References (123)

1. Mackenzie J.S., Gubler D.J., and Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10 (2004) S98-S109
2. Halstead S.B. Dengue. Lancet 370 9599 (2007) 1644-1652
3. Lindsey N.P., Kuhn S., Campbell G.L., and Hayes E.B. Neuroinvasive disease incidence in the United States, 2002-2006. Vector-Borne Zoonotic Dis 8 1 (2008) 35-39
4. Murray K.O., Baraniuk S., Resnick M., Arafat R., Kilborn C., Shallenberger R., et al. Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004. Vector-Borne Zoonotic Dis 8 2 (2008) 167-174
5. Monath T.P. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci 951 (2001) 1-12
6. van den Hurk A.F., Ritchie S.A., and Mackenzie J.S. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 54 (2009) 17-35
7. van-den-Hurk A.F., Ritchie S.A., Johansen C.A., Mackenzie J.S., and Smith G.A. Domestic pigs and Japanese encephalitis virus infection, Australia. Emerg Infect Dis 14 11 (2008) 1736-1738
8. Halstead S.B., and Jacobson J. Japanese encephalitis vaccines. In: Plotkin S.A., Orenstein W.A., and Offit P.A. (Eds). Vaccines. 5th ed. (2008), Saunders Elsevier, Philadelphia, PA 311-352
9. Monath T.P. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Topics Microbiol Immunol 267 (2002) 105-138
10. Pugachev K.V., Guirakhoo F., and Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 18 5 (2005) 387-394
11. Eckels K.H., Yu Y.X., Dubois D.R., Marchette N.J., Trent D.W., and Johnson A.J. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cells cultures and preparation of a vaccine for human use. Vaccine 6 (1988) 513-518
12. Whitehead S.S., Blaney J.E., Durbin A.P., and Murphy B.R. Prospects for a dengue virus vaccine. Nat Rev Microbiol 5 7 (2007) 518-528
13. Guy B., and Almond J.W. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 31 2-3 (2008) 239-252
14. Dauphin G., and Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 25 30 (2007) 5563-5576
15. Beasley D.W., Lewthwaite P., and Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 8 1 (2008) 95-106
16. Delagrave S., and Guirakhoo F. Research and development of chimeric flavivirus vaccines. In: Georgiev V.St., Western K.A., and McGowan J.J. (Eds). NIAID, NIH, vol. 1, Frontiers in Research (2008), Humana Press 459-473
17. Chambers T.J., Nestorowicz A., Mason P.W., and Rice C.M. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73 4 (1999) 3095-3101
18. Guirakhoo F., Zhang Z.X., Chambers T.J., Delagrave S., Arroyo J., Barrett A.D., et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257 2 (1999) 363-372
19. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74 12 (2000) 5477-5485
20. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78 22 (2004) 12497-12507
21. Monath T.P., Levenbook I., Soike K., Zhang Z.X., Ratterree M., Draper K., et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 74 4 (2000) 1742-1751
22. Caufour P.S., Motta M.C., Yamamura A.M., Vazquez S., Ferreira I.I., Jabor A.V., et al. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 79 1-2 (2001) 1-14
23. Bonaldo M.C., Caufour P.S., Freire M.S., and Galler R. The yellow fever 17D vaccine virus as a vector for the expression of foreign proteins: development of new live flavivirus vaccines. Mem Inst Oswaldo Cruz 95 Suppl. 1 (2000) 215-223
24. Chambers T.J., Liang J., Droll D.A., Schlesinger J.A., Davidson A.D., Wright P.J., et al. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol 77 (2003) 3655-3668
25. van der Most R.G., Murali-Krishna K., Ahmed R., and Strauss J.H. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74 (2000) 8094-8101
26. Galler R., Marchevsky R.S., Caride E., Almeida L.F.C., Yamamura A.M.Y., Jabor A.V., et al. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys. Braz J Med Biol Res 38 12 (2005) 1835-1846
27. Guy B, Guirakhoo F, Watson M, Higgs S, Monath TP. Safety of flavivirus chimeric vaccines: answer to Ishikawa et al. [Vaccine 26 (22) (2008) 2772-2781]. Vaccine 2008;26:4107-8.
28. Lehrman S. Nature 401 (1999) 517-518
29. Barban V., Girerd Y., Aguirre M., Gulia S., Pétiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 25 15 (2007) 2941-2950
30. Mantel N., Aguirre M., Gulia S., Girerd-Chambaz Y., Colombani S., Moste C., et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 151 1 (2008) 40-46
31. Zhang Y., Corver J., Chipman P.R., Zhang W., Pletnev S.V., Sedlak D., et al. Structure of immature flavivirus particles. EMBO J. 11 (2003) 2604-2613
32. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 5 (2002) 717-725
33. Halstead S.B., Marchette N.J., Diwan A.R., Palumbo N.E., Putvatana R., and Larsen L.K. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells. Am J Trop Med Hyg 4 (1984) 672-678
34. Sirigulpanit W., Kinney R.M., and Leardkamolkarn V. Substitution or deletion mutations between nt 54 and 70 in the 5' non-coding region of dengue type 2 virus produce variable effects on virus viability. J Gen Virol 88 6 (2007) 1748-1752
35. Eckels K.H., Yu Y.X., Dubois D.R., Marchette N.J., Trent D.W., and Johnson A.J. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 6 6 (1988) 513-518
36. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., et al. High fidelity of yellow fever virus RNA polymerase. J Virol 78 (2004) 1032-1038
37. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 8 (2004) 4761-4775
38. Miller B.R., and Atkins D. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice. Acta Virol 32 (1988) 227-234
39. Vlaycheva L.A., and Chambers T.J. Neuroblastma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol 76 (2002) 6172-6184
40. Arroyo J., Guirakhoo F., Fenner S., Zhang Z.X., Monath T.P., and Chambers T.J. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75 2 (2001) 934-942
41. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103 17 (2006) 6694-6699
42. Green S., and Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19 (2006) 429-436
43. Libraty D.H., Pichyangkul S., Ajariyakhajorn C., Endy T.P., and Ennis F.A. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 75 (2001) 3501-3508
44. Palmer D.R., Sun P., Celluzzi C., Bisbing J., Pang S., Sun W., et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 79 4 (2005) 2432-2439
45. Brandler S., Brown N., Ermak T.H., Mitchell F., Parsons M., Zhang Z., et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 72 1 (2005) 74-81
46. Deauvieau F., Sanchez V., Balas C., Kennel A., de Montfort A., Lang J., et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow fever dengue vaccines serotype 1 to 4. Am J Trop Med Hyg 76 (2007) 144-154
47. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 33 3 (2005) 131-144
48. Beasley D.W., Li L., Suderman M.T., Guirakhoo F., Trent D.W., Monath T.P., et al. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22 27-28 (2004) 3722-3726
49. De Groot A.S., Martin W., Moise L., Guirakhoo F., and Monath T. Analysis of ChimeriVax Japanese encephalitis virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine 25 47 (2007) 8077-8084
50. Lobigs M., Larena M., Alsharifi M., Lee E., and Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. J Virol 83 (2009) 2436-2445
51. Morrey J.D., Siddharthan V., Olsen A.L., Roper G.Y., Wang H., Baldwin T.J., et al. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194 9 (2006) 1300-1308
52. Xiao S.-Y., Guzman H., Zhang H., Travassos da A.P.A., and Tesh R.B. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 7 (2001) 714-721
53. Tesh R.B., Arroyo J., Travassos da Rosa A.P.A., Guzman H., Xiao S.-Y., and Monath T.P. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 8 (2002) 1392-1397
54. WHO Technical report series, N° 872; 1998.
55. Monath T.P., Soike K., Levenbook I., Zhang Z.X., Arroyo J., Delagrave S., et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17 15-16 (1999) 1869-1882
56. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75 (2001) 7290-7304
57. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 (2000) 2-9
58. Mason R.A., Tauraso N.M., Spertzel R.O., and Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25 4 (1973) 539-544
59. Monath T.P., Cetron M.S., McCarthy K., Nichols R., Archambault W.T., Weld L., et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1 5 (2005) 207-214
60. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189 6 (2004) 990-1000
61. Guy B., Barban V., Mantel M., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80 2 (2009) 302-311
62. Morrison D, Capeding MR, Poo JL, Forrat R, Dumas R, Lang J. Safety and infectivity of tetravalent chimeric live attenuated dengue vaccine in different age populations in endemic and non-endemic areas. ASTMH 56th meeting 2007, Abstract # 344.
63. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2 (2006) 60-67
64. Sabin A.B. Research on dengue during World War II. Am J Trop Med Hyg 1 1 (1952) 30-50
65. Halstead S.B., and O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265 (1977) 739-741
66. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 (1989) 444-451
67. Mangada M.M., Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., Libraty D.H., et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 185 12 (2002) 1697-1703
68. Mangada M.M., and Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 175 4 (2005) 2676-2683
69. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26 45 (2008) 5712-5721
70. Mongkolsapaya J., Dejnirattisai W., Xu X.N., Vasanawathana S., Tangthawornchaikul N., Chairunsri A., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9 (2003) 921-927
71. Monath T.P., McCarthy K., Bedford P., Johnson C.T., Nichols R., Yoksan S., et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20 7-8 (2002) 1004-1018
72. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188 8 (2003) 1213-1230
73. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. WHO, Geneva. 2-3 September 2004. Vaccine 23 45 (2005) 5205-5211
74. World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol Rec 81 34/35 (2006) 331-340
75. Murali-Krishna K., Ravi V., and Manjunath R. Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J Gen Virol 77 4 (1996) 705-714
76. Desai A., Ravi V., Chandramuki A., and Gourie-Devi M. Proliferative response of human peripheral blood mononuclear cells to Japanese encephalitis virus. Microbiol Immunol 39 4 (1995) 269-273
77. Kumar P., Krishna V.D., Sulochana P., Nirmala G., Haridattatreya M., and Satchidanandam V. Cell-mediated immune responses in healthy children with a history of subclinical infection with Japanese encephalitis virus: analysis of CD4+ and CD8+ T cell target specificities by intracellular delivery of viral proteins using the human immunodeficiency virus Tat protein transduction domain. J Gen Virol 85 (2004) 471-482
78. Bhatt T.R., Crabtree M.B., Guirakhoo F., Monath T.P., and Miller B.R. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg 62 4 (2000) 480-484
79. Johnson B.W., Chambers T.V., Crabtree M.B., Arroyo J., Monath T.P., and Miller B.R. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol 17 3 (2003) 235-243
80. Johnson B.W., Chambers T.V., Crabtree M.B., Bhatt T.R., Guirakhoo F., Monath T.P., et al. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 67 3 (2002) 260-265
81. Johnson B.W., Chambers T.V., Crabtree M.B., Guirakhoo F., Monath T.P., and Miller B.R. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 70 1 (2004) 89-97
82. Higgs S., Vanlandingham D.L., Klingler K.A., McElroy K.L., McGee C.E., Harrington L., et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg 75 5 (2006) 986-993
83. McGee C.E., Tsetsarkin K., Vanlandingham D., McElroy K.L., Lang J., Guy B., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-Dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 197 (2008) 686-692
84. Roubaud E., Colas-Belcour J., and Stefanopoulo G.J. Transmission de la fièvre jaune par un moustique palearetique répandu dans la région parisienne, l' Aedes geniculatus Oliv. C R Acad Sci 205 (1937) 182-189
85. Whitman L. Multiplication of the virus of yellow fever in Aedes aegypti. J Exp Med 66 (1937) 133-143
86. Whitman L. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med Hyg 19 (1939) 19-26
87. Jennings A.D., Gibson C.A., Miller B.R., Mathews J.H., Mitchell C.J., Roehrig J.T., et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169 (1994) 512-518
88. McElroy K.L., Tsetsarkin K., Vanlandingham D.L., and Higgs S. Role of the Yellow Fever Virus Structural Protein Genes in Viral Dissemination from the Aedes aegypti Mosquito Midgut. J Gen Virol 87 (2006) 2993-3001
89. McElroy K.L., Tsetsarkin K., Vanlandingham D.L., and Higgs S. Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3′non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut. Am J Trop Med Hyg 75 (2006) 1158-1164
90. McElroy K.L., Girard Y.A., McGee C.E., Tsetsarkin K.A., Vanlandingham D.L., and Higgs S. Characterization of the antigen distribution and tissue tropisms of three phenotypically distinct yellow fever virus variants in orally infected Aedes aegypti mosquitoes. Vector-Borne Zoonotic Dis 8 (2008) 675-687
91. Davis N.C., Lloyd W., and Frobisher Jr. M. Transmission of neurotropic yellow fever virus by Stegomyia mosquitoes. J Exp Med 56 (1932) 853-865
92. Roubaud E., and Stephanopoulo G.J. Recherches sur la transmission par la voie stegomyienne du virus neurotrope murin de la fièvre jaune. Bull Soc Pathol Exot 26 (1933) 305-309
93. Peltier M., Durieux C., Jonchere H., and Arquie E. La transmission par piqure de Stegomyia, du virus amaril neurotrope présent dans le sang des personnes récemment vaccinées, est-elle possible dans les régions ou ce moustique existe en abondance?. Rev d'Immunol 5 (1939) 172-195
94. Aitken T.H., Downs W.G., and Shope R.E. Aedes aegypti strain fitness for yellow fever virus transmission. Am J Trop Med Hyg 26 (1977) 985-989
95. Beaty B.J., and Aitken T.H.G. In vitro transmission of yellow fever virus by geographic strains of Aedes aegypti. Mosquito News 39 (1979) 232-238
96. Tabachnick W.J., Wallis G.P., Aitken T.H., Miller B.R., Amato G.D., Lorenz L., et al. Oral infection of Aedes aegypti with yellow fever virus: geographic variation and genetic considerations. Am J Trop Med Hyg 34 (1985) 1219-1224
97. McElroy K.L., Tsetsarkin K.A., Vanlandingham D.L., and Higgs S. Characterization of yellow fever virus-mosquito interactions using an infectious clone of the wild-type Asibi virus. J Gen Virol 86 (2005) 1747-1751
98. Reid M., Mackenzie D., Baron A., Lehmann N., Lowry K., Aaskov J., et al. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg 75 4 (2006) 659-663
99. Langevin S.A., Arroyo J., Monath T.P., and Komar N. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus Ossifragus). Am J Trop Med Hyg 69 1 (2003) 78-80
100. Hahn C.S., Dalrymple J.M., Strauss J.H., and Rice C.M. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci USA 84 7 (1987) 2019-2023
101. dos Santos C.N., Post P.R., Carvalho R., Ferreira I.I., Rice C.M., and Galler R. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 35 1 (1995) 35-41
102. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 101 10 (2007) 967-971
103. Seligman S.J., and Gould E.A. Live flavivirus vaccines: reasons for caution. Lancet 363 9426 (2004) 2073-2075
104. Seligman S.J., and Gould E.A. Safety concerns with regard to live attenuated flavivirus vaccines. J Infect Dis 198 5 (2008) 794-795
105. Monath T.P., Kanesa-Thasan N., Guirakhoo F., Pugachev K., Almond J., Lang J., et al. Recombination and flavivirus vaccines: a commentary. Vaccine 23 23 (2005) 2956-2958
106. Hombach J., Kurane I., and Wood D. Arguments for live flavivirus vaccines. Lancet 364 9433 (2004) 498-499
107. Pugachev K.V., Schwaiger J., Brown N., Zhang Z.X., Catalan J., Mitchell F.S., et al. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE). Vaccine 25 37-38 (2007) 6661-6671
108. McGee C.E., Lewis M.G., Claire MSt., Wagner W., Lang J., Guy B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 197 (2008) 693-697
109. Lefeuvre A. Caractérisation des interactions entre les cellules hépatiques et les souches sauvage et vaccinale du virus de la fièvre jaune: application à l'étude de virus fièvre jaune chimériques utilisés pour le développement d'un vaccin contre la dengue. Diplôme de Doctorat 2005; Université Claude Bernard Lyon 1, N° 129-2005.
110. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 26 48 (2008) 6077-6082
111. Edelman R., and Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Summary of a WHO technical consultation. Vaccine 26 (2008) 4113-4119
112. Guy B., Chanthavanich P., Gimenez S., Sirivichayakul C., Sabchareon A., Begue S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22 27-28 (2004) 3563-3574
113. Laoprasopwattana K., Libraty D.H., Endy T.P., Nisalak A., Chunsuttiwat S., Vaughn D.W., et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 192 3 (2005) 510-519
114. Chanthavanich P., Luxemburger C., Sirivichayakul C., Lapphra K., Pengsaa K., Yoksan, et al. Short report: immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 75 1 (2006) 26-28
115. Gibbons R.V., Kalanarooj S., Jarman R.G., Nisalak A., Vaughn D.W., Endy T.P., et al. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 77 5 (2007) 910-913
116. Guilarde A.O., Turchi M.D., Siqueira Jr. J.B., Feres V.C., Rocha B., Levi J.E., et al. Dengue and dengue hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. J Infect Dis 197 6 (2008) 817-824
117. Sun W. Meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines. Bangkok, Thailand; October 2004.
118. Kyle J.L., Balsitis S.J., Zhang L., Beatty P.R., and Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380 (2008) 296-303
119. Guy B, Barban V, Lang J. Preclinical research and evaluation of dengue vaccine candidates. PDVI; in press.
120. Galler R., Freire M.S., Jabor A.V., and Mann G.F. The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector. Braz J Med Biol Res 30 2 (1997) 157-168
121. Xie H., Cass A.R., and Barrett A.D. Yellow fever 17D vaccine virus isolated from healthy vaccinees accumulates very few mutations. Virus Res 55 1 (1998) 93-99
122. Twiddy S.S., and Holmes E.C. The extent of homologous recombination in members of the genus Flavivirus. J Gen Virol 84 2 (2003) 429-440
123. Barban V, Girerd Y, Mantel M, Aguirre M, Petiard F, Colombani S, et al. Replication and temperature-sensitivity profiles on Vero, Huh-7 and HepG2 cells, of different wild-type compared to either Dengue virus attenuated strains, or chimeric YF viruses presenting Dengue envelope. Abstract #458. 55th ASTMH meeting Atlanta; 2006.